- Home
- Publications
- Publication Search
- Publication Details
Title
Functional Gene Variants of CYP3A4
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 96, Issue 3, Pages 340-348
Publisher
Springer Nature
Online
2014-06-13
DOI
10.1038/clpt.2014.129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450
- (2014) V. Lamba et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22
- (2014) Simon D. Baxter et al. BREAST CANCER RESEARCH AND TREATMENT
- Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
- (2014) M H M Diekstra et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
- (2014) Ingrid Lunde et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The Influence of the CYP3A4*22 Polymorphism on Serum Concentration of Quetiapine in Psychiatric Patients
- (2014) Karen van der Weide et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study
- (2014) Daniel T. Barratt et al. Pharmacogenetics and Genomics
- CYP3A5andCYP3A4, but notABCB1polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients
- (2014) Mateusz Kurzawski et al. PHARMACOGENOMICS
- Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients
- (2013) Leszek Pączek Annals of Transplantation
- Influence of Cytochrome P450 (CYP) 3A4*1G Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients
- (2013) Miwa Uesugi et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
- (2013) Wendy A. Teft et al. BREAST CANCER RESEARCH AND TREATMENT
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- (2013) Maria Alice V. Willrich et al. CLINICA CHIMICA ACTA
- CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
- (2013) A.-J. M. de Graan et al. CLINICAL CANCER RESEARCH
- Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients
- (2013) J.-B. Woillard et al. CLINICAL CHEMISTRY
- Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance
- (2013) A N Werk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control
- (2013) Chris Stockmann et al. JOURNAL OF PEDIATRICS
- A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients
- (2013) Beatriz Tavira et al. Pharmacogenetics and Genomics
- CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
- (2013) Laure Elens et al. PHARMACOGENOMICS
- CYP3A4*22andCYP3Acombined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients
- (2013) Violette MGJ Gijsen et al. PHARMACOGENOMICS
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes
- (2012) Zhao Mao et al. BIOCHEMICAL PHARMACOLOGY
- PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
- (2012) Kathrin Klein et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
- (2012) Leslie J. Dickmann et al. CURRENT DRUG METABOLISM
- Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers
- (2012) Jing-Jing Zhang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients
- (2012) Yunying Shi et al. GENE
- Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia
- (2012) Zhican Wang et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia
- (2012) Miao Hu et al. PHARMACOGENOMICS
- Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation
- (2012) Guillermo Gervasini et al. TRANSPLANT INTERNATIONAL
- NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation
- (2012) Katherine A. Barraclough et al. TRANSPLANTATION
- A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
- (2011) L. Elens et al. CLINICAL CHEMISTRY
- Analysis of CYP3A4 genetic polymorphisms in Han Chinese
- (2011) Qing Zhou et al. JOURNAL OF HUMAN GENETICS
- Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
- (2011) Laure Elens et al. Pharmacogenetics and Genomics
- Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
- (2011) Laure Elens et al. PHARMACOGENOMICS
- Effects of a Commonly Occurring Genetic Polymorphism of Human CYP3A4 (I118V) on the Metabolism of Anandamide
- (2010) M. Pratt-Hyatt et al. DRUG METABOLISM AND DISPOSITION
- Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis
- (2010) X.-J. Shi et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- Association of genotypes of the CYP3A cluster with midazolam disposition in vivo
- (2009) J Miao et al. PHARMACOGENOMICS JOURNAL
- The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density
- (2008) YS Kang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone
- (2008) M. Miyazaki et al. DRUG METABOLISM AND DISPOSITION
- Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients
- (2008) Xiao-yan Qiu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started